| Cod Nacion | Nro Definitivo | Des Nomco | Des Prese | Cod Vtm | Cod Vmp | Cod Vmpp | Des Dosific | Cod Forfar | Cod Forfar Simplificada | Cod Envase | Contenido | Unid Contenido | Nro Conte | Cod Atc | Sw Psicotropo | Sw Estupefaciente | Sw Afecta Conduccion | Sw Triangulo Negro | Url Fictec | Url Prosp | Sw Receta | Sw Generico | Sw Sustituible | Sw Envase Clinico | Sw Uso Hospitalario | Sw Diagnostico Hospitalario | Sw Tld | Sw Especial Control Medico | Sw Huerfano | Sw Base A Plantas | Laboratorio Titular | Laboratorio Comercializador | Fecha Autorizacion | Sw Comercializado | Cod Sitreg | Cod Sitreg Presen | Fecha Situacion Registro | Fec Sitreg Presen | Sw Tiene Excipientes Decl Obligatoria | Nro Pactiv | Fec Comer | Lista Psicotropo | Cod Nacionales Inactivos | Lista Estupefaciente | Hash | Last Modified | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 767479 | 1211594002 | RYBREVANT 1600 MG SOLUCION INYECTABLE | RYBREVANT 1600 MG SOLUCION INYECTABLE, 1 vial de 10 ml | 1600 mg inyectable 10 ml | 45 | 1 | 34 | 1 vial de 10 ml | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1211594002/1211594002_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1211594002/1211594002_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6153 | JANSSEN CILAG S.A. | 2025-04-14 | 1 | 1 | 1 | 2025-04-15 | 2025-04-14 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 767480 | 1211594003 | RYBREVANT 2240 MG SOLUCION INYECTABLE | RYBREVANT 2240 MG SOLUCION INYECTABLE, 1 vial de 14 ml | 2240 mg inyectable 14 ml | 45 | 1 | 34 | 1 vial de 14 ml | 0 | 0 | 1 | 1 | https://cima.aemps.es/cima/pdfs/es/ft/1211594003/1211594003_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/1211594003/1211594003_p.pdf | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6153 | JANSSEN CILAG S.A. | 2025-04-14 | 1 | 1 | 1 | 2025-04-15 | 2025-04-14 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 768819 | 99125002IP2 | ZYPREXA VELOTAB 10 MG COMPRIMIDOS BUCODISPERSABLES | ZYPREXA VELOTAB 10 MG COMPRIMIDOS BUCODISPERSABLES, 28 comprimidos | 10 mg | 5 | 28 | 10 | 28 comprimidos | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/99125002IP2/99125002IP2_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/99125002IP2/99125002IP2_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44757 | ECOFAR PRODUCTOS S.L. | 2025-10-20 | 1 | 1 | 1 | 2025-10-21 | 2025-10-20 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 768821 | 99125006IP2 | ZYPREXA VELOTAB 10 MG COMPRIMIDOS BUCODISPERSABLES | ZYPREXA VELOTAB 10 MG COMPRIMIDOS BUCODISPERSABLES, 56 comprimidos | 10 mg | 5 | 56 | 10 | 56 comprimidos | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/99125006IP2/99125006IP2_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/99125006IP2/99125006IP2_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44757 | ECOFAR PRODUCTOS S.L. | 2025-10-20 | 1 | 1 | 1 | 2025-10-21 | 2025-10-20 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 768857 | 96022010IP3 | ZYPREXA 10 MG COMPRIMIDOS RECUBIERTOS | ZYPREXA 10 MG COMPRIMIDOS RECUBIERTOS, 56 comprimidos | 10 mg | 5 | 56 | 10 | 56 comprimidos | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/96022010IP3/96022010IP3_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/96022010IP3/96022010IP3_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44757 | ECOFAR PRODUCTOS S.L. | 2025-10-21 | 1 | 1 | 1 | 2025-10-22 | 2025-10-21 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 768858 | 96022009IP2 | ZYPREXA 10 MG COMPRIMIDOS RECUBIERTOS | ZYPREXA 10 MG COMPRIMIDOS RECUBIERTOS, 28 comprimidos | 10 mg | 5 | 28 | 10 | 28 comprimidos | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/96022009IP2/96022009IP2_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/96022009IP2/96022009IP2_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44757 | ECOFAR PRODUCTOS S.L. | 2025-10-21 | 1 | 1 | 1 | 2025-10-22 | 2025-10-21 | 1 | 2025-11-12 | View Edit Delete | ||||||||||||
| 759864 | 88386 | INTESTIFALK 4 MG SUPOSITORIOS | INTESTIFALK 4 MG SUPOSITORIOS, 30 supositorios (PVC/LDPE) | 4 mg | 42 | 30 | 33 | 30 supositorios (PVC/LDPE) | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/88386/88386_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/88386/88386_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28572 | DR. FALK PHARMA ESPANA S.L. | 2023-03-07 | 1 | 1 | 1 | 2023-03-07 | 2023-03-07 | 0 | 2025-11-11 | View Edit Delete | ||||||||||||
| 764008 | 89231 | TACGALEN 1 MG/ML EMULSIÓN CUTÁNEA | TACGALEN 1 MG/ML EMULSIÓN CUTÁNEA, 60 ml | 1 mg/ml | 6 | 60 | 26 | 60 ml | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/89231/89231_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/89231/89231_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67780 | GALENICUM DERMA S.L. | 2024-01-09 | 1 | 1 | 1 | 2024-01-10 | 2024-01-09 | 1 | 2025-11-11 | View Edit Delete | ||||||||||||
| 766538 | 90033 | LERCANIDIPINO PENSA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG | LERCANIDIPINO PENSA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidos | 20 mg | 5 | 28 | 10 | 28 comprimidos | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/90033/90033_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/90033/90033_p.pdf | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40831 | TOWA PHARMACEUTICAL S.A. | 2024-12-27 | 1 | 1 | 1 | 2024-12-28 | 2024-12-27 | 1 | 2025-11-11 | View Edit Delete | ||||||||||||
| 767711 | 86458 | MUPIROCINA GALENICUMDERMA 20 MG/G POMADA | MUPIROCINA GALENICUMDERMA 20 MG/G POMADA, 1 tubo de 30 g | 20 mg/g | 44 | 30 | 21 | 1 tubo de 30 g | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/86458/86458_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/86458/86458_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67780 | GALENICUM DERMA S.L.U. | 2021-12-21 | 1 | 1 | 1 | 2021-12-22 | 2025-05-13 | 0 | 2025-11-11 | View Edit Delete | ||||||||||||
| 768840 | 62721 | NERVIKAN COMPRIMIDOS RECUBIERTOS | NERVIKAN COMPRIMIDOS RECUBIERTOS, 60 comprimidos | 80 mg/160 mg | 5 | 60 | 10 | 60 comprimidos | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/62721/62721_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/62721/62721_p.pdf | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 867 | SCHWABE FARMA IBERICA S.A. | 1999-09-01 | 1 | 1 | 1 | 1999-09-01 | 2025-10-17 | 1 | 2025-11-11 | View Edit Delete | ||||||||||||
| 607767 | 54626 | AMITRON 500 MG CÁPSULAS DURAS | AMITRON 500 MG CÁPSULAS DURAS, 100 cápsulas | 500 mg | 5 | 100 | 43 | 100 cápsulas | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/54626/54626_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/54626/54626_p.pdf | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1626 | LAPHYSAN S.A.U. | 1980-05-01 | 1 | 1 | 1 | 2013-10-28 | 2024-03-07 | 0 | 2025-11-10 | View Edit Delete | ||||||||||||
| 724868 | 68367 | MATRIFEN 100 microgramos/HORA PARCHE TRANSDERMICO | MATRIFEN 100 microgramos/HORA PARCHE TRANSDERMICO, 5 parches (Papel/aluminio/PET/PE) | 100 microgramos/h | 35 | 5 | 28 | 5 parches (Papel/aluminio/PET/PE) | 0 | 1 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/68367/68367_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/68367/68367_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51521 | PHARMA INTERNATIONAL S.A. | 2007-01-18 | 1 | 1 | 1 | 2007-01-18 | 2019-02-19 | 1 | 2025-11-10 | Lista I | View Edit Delete | |||||||||||
| 724870 | 68364 | MATRIFEN 25 microgramos/HORA PARCHE TRANSDERMICO | MATRIFEN 25 microgramos/HORA PARCHE TRANSDERMICO, 5 sobres (Papel/Aluminio/PET/PE) | 25 microgramos/h | 35 | 5 | 28 | 5 sobres (Papel/Aluminio/PET/PE) | 0 | 1 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/68364/68364_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/68364/68364_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51521 | PHARMA INTERNATIONAL S.A. | 2007-01-18 | 1 | 1 | 1 | 2007-01-18 | 2019-02-19 | 1 | 2025-11-10 | Lista I | View Edit Delete | |||||||||||
| 724873 | 68366 | MATRIFEN 75 microgramos/HORA PARCHE TRANSDERMICO | MATRIFEN 75 microgramos/HORA PARCHE TRANSDERMICO, 5 sobres (Papel/Aluminio/PET/PE) | 75 microgramos/h | 35 | 5 | 28 | 5 sobres (Papel/Aluminio/PET/PE) | 0 | 1 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/68366/68366_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/68366/68366_p.pdf | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51521 | PHARMA INTERNATIONAL S.A. | 2007-01-18 | 1 | 1 | 1 | 2007-01-18 | 2019-02-19 | 1 | 2025-11-10 | Lista I | View Edit Delete | |||||||||||
| 764314 | 89350 | PAZOPANIB ACCORD 200 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG | PAZOPANIB ACCORD 200 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG, 30 comprimidos | 200 mg | 5 | 30 | 10 | 30 comprimidos | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/89350/89350_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/89350/89350_p.pdf | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2024-02-14 | 1 | 1 | 1 | 2024-02-15 | 2024-02-14 | 1 | 2025-11-10 | View Edit Delete | ||||||||||||
| 764315 | 89351 | PAZOPANIB ACCORD 400 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG | PAZOPANIB ACCORD 400 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG, 60 comprimidos | 400 mg | 5 | 60 | 10 | 60 comprimidos | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/89351/89351_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/89351/89351_p.pdf | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 11104 | ACCORD HEALTHCARE S.L.U. | 2024-02-14 | 1 | 1 | 1 | 2024-02-15 | 2024-02-14 | 1 | 2025-11-10 | View Edit Delete | ||||||||||||
| 769098 | 09609002IP | ELONVA 150 MICROGRAMOS SOLUCION INYECTABLE | ELONVA 150 MICROGRAMOS SOLUCION INYECTABLE, 1 jeringa precargada de 0,5 ml | 150 microgramos | 33 | 1 | 61 | 1 jeringa precargada de 0,5 ml | 0 | 0 | 0 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/09609002IP/09609002IP_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/09609002IP/09609002IP_p.pdf | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 48716 | ABACUS MEDICINE A/S | 2025-11-07 | 1 | 1 | 1 | 2025-11-08 | 2025-11-07 | 1 | 2025-11-10 | View Edit Delete | ||||||||||||
| 766966 | 90149 | POMALIDOMIDA STADA 3 MG CÁPSULAS DURAS EFG | POMALIDOMIDA STADA 3 MG CÁPSULAS DURAS EFG, 21 cápsulas (PVC/PCTFE/Aclar/Al) | 3 mg | 5 | 21 | 43 | 21 cápsulas (PVC/PCTFE/Aclar/Al) | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/90149/90149_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/90149/90149_p.pdf | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6220 | LABORATORIO STADA S.L. | 2025-02-18 | 1 | 1 | 1 | 2025-02-19 | 2025-02-18 | 1 | 2025-11-07 | View Edit Delete | ||||||||||||
| 766970 | 90150 | POMALIDOMIDA STADA 4 MG CÁPSULAS DURAS EFG | POMALIDOMIDA STADA 4 MG CÁPSULAS DURAS EFG, 21 cápsulas (PVC/PCTFE/Aclar/Al) | 4 mg | 5 | 21 | 43 | 21 cápsulas (PVC/PCTFE/Aclar/Al) | 0 | 0 | 1 | 0 | https://cima.aemps.es/cima/pdfs/es/ft/90150/90150_ft.pdf | https://cima.aemps.es/cima/pdfs/es/p/90150/90150_p.pdf | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6220 | LABORATORIO STADA S.L. | 2025-02-18 | 1 | 1 | 1 | 2025-02-19 | 2025-02-18 | 1 | 2025-11-07 | View Edit Delete |
Page 46 of 1036, showing 20 records out of 20709 total, starting on record 901, ending on 920